| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | BII; CACH6; Cav2.3; CACNL1A6 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CACNA1E |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CACNA1E抗体的3篇参考文献示例(注：内容为虚构，仅供格式参考)：
1. **"CACNA1E Antibody Validation in Neuronal Calcium Channel Studies"**
- 作者：Smith J, et al.
- 摘要：研究验证了一种新型CACNA1E抗体的特异性，通过免疫印迹和免疫组化证实其在检测人类和小鼠脑组织中的CaV2.3通道蛋白表达的可靠性，并探讨其与癫痫模型的相关性。
2. **"Role of CACNA1E in Autism Spectrum Disorder: An Immunohistochemical Analysis"**
- 作者：Lee S, et al.
- 摘要：利用CACNA1E抗体分析自闭症患者脑组织样本，发现CaV2.3蛋白表达水平异常升高，提示其在神经突触功能异常中的潜在作用。
3. **"CACNA1E as a Biomarker for Neuropathic Pain: Antibody-Based Detection in Clinical Samples"**
- 作者：Garcia R, et al.
- 摘要：通过CACNA1E抗体检测发现，慢性疼痛患者的背根神经节中CaV2.3通道表达显著上调，表明其可作为疼痛治疗的潜在靶点。
如需真实文献，建议通过PubMed或Google Scholar以“CACNA1E antibody”或“CaV2.3 antibody”为关键词检索。
The CACNA1E gene encodes the α1E subunit of voltage-gated calcium channels (CaV2.3), which form R-type calcium channels critical for regulating cellular excitability, neurotransmitter release, and gene expression. Antibodies targeting CACNA1E are essential tools for studying the expression, localization, and function of these channels in tissues, particularly in the nervous system. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate channel distribution in neurons, endocrine cells, and other excitable cells.
CACNA1E has been implicated in neurological disorders, including epilepsy, autism spectrum disorders, and chronic pain, as well as certain cancers due to its dysregulated expression. Research-grade CACNA1E antibodies help elucidate its role in disease mechanisms, synaptic plasticity, and calcium signaling pathways. However, challenges persist due to the channel’s structural complexity, splice variants, and post-translational modifications, which demand antibody specificity validation. Reliable CACNA1E antibodies are crucial for distinguishing CaV2.3 from other calcium channel subtypes and advancing translational studies exploring therapeutic targeting. Recent studies also highlight its potential as a biomarker, driving demand for high-affinity, well-characterized antibodies in both basic research and clinical diagnostics.
×
